Enliven Therapeutics Inc. (Nasdaq: ELVN) reported this week that as of the end of 2025, the clinical-stage precision oncology ...
Reported positive initial Phase 1b data for ELVN-001 in CML Initiation of the Phase 3 ENABLE-2 pivotal trial of ELVN-001 ...
Biosimulation results highlight how model-informed approaches for drug development and regulatory decision-making save time and money.RADNOR, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Certara, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results